AP9701148A0 - Dimesylate salts of neuropeptide Y ligands. - Google Patents
Dimesylate salts of neuropeptide Y ligands.Info
- Publication number
- AP9701148A0 AP9701148A0 APAP/P/1997/001148A AP9701148A AP9701148A0 AP 9701148 A0 AP9701148 A0 AP 9701148A0 AP 9701148 A AP9701148 A AP 9701148A AP 9701148 A0 AP9701148 A0 AP 9701148A0
- Authority
- AP
- ARIPO
- Prior art keywords
- neuropeptide
- ligands
- dimesylate
- salts
- dimesylate salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3181596P | 1996-11-26 | 1996-11-26 | |
| PCT/IB1997/001465 WO1998023603A1 (en) | 1996-11-26 | 1997-11-19 | Dimesylate salts of neuropeptide y ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP9701148A0 true AP9701148A0 (en) | 1998-01-31 |
Family
ID=21861551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1997/001148A AP9701148A0 (en) | 1996-11-26 | 1997-11-20 | Dimesylate salts of neuropeptide Y ligands. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5914329A (enExample) |
| EP (1) | EP0944611B1 (enExample) |
| JP (1) | JP3120861B2 (enExample) |
| AP (1) | AP9701148A0 (enExample) |
| AR (1) | AR010304A1 (enExample) |
| AT (1) | ATE257472T1 (enExample) |
| AU (1) | AU4792497A (enExample) |
| BR (1) | BR9713538A (enExample) |
| CA (1) | CA2272927C (enExample) |
| DE (1) | DE69727155T2 (enExample) |
| DK (1) | DK0944611T3 (enExample) |
| ES (1) | ES2213207T3 (enExample) |
| GT (1) | GT199700123A (enExample) |
| HN (1) | HN1997000154A (enExample) |
| HR (1) | HRP970640A2 (enExample) |
| ID (1) | ID18964A (enExample) |
| MA (1) | MA26450A1 (enExample) |
| PA (1) | PA8441701A1 (enExample) |
| PE (1) | PE17099A1 (enExample) |
| PT (1) | PT944611E (enExample) |
| TN (1) | TNSN97191A1 (enExample) |
| WO (1) | WO1998023603A1 (enExample) |
| ZA (1) | ZA9710587B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001232900A1 (en) * | 2000-01-20 | 2001-07-31 | Michael Amling | Methods and compositions for control of bone formation via modulation of neuropeptide y activity |
| US20060165683A1 (en) | 2001-12-05 | 2006-07-27 | Gerard Karsenty | Methods and compositions for control of bone formation via modulation of sympathetic tone |
| US7273703B2 (en) | 2002-01-09 | 2007-09-25 | Funbogen Ab | Detection of mutations |
| EP1814593A4 (en) * | 2004-11-23 | 2012-09-05 | Dong Wha Pharm Co Ltd | ORAL PREPARATION HAVING IMPROVED BIOAVAILABILITY |
| AU2006235200A1 (en) * | 2005-04-15 | 2006-10-19 | Regenertech Pty Limited | Use of Neuropeptide Y (NPY) and agonists and antagonists thereof for tissue regeneration |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ137297A3 (cs) * | 1994-11-07 | 1998-04-15 | Pfizer Inc. | Substituované benzylaminové deriváty |
-
1997
- 1997-11-18 US US08/972,470 patent/US5914329A/en not_active Expired - Fee Related
- 1997-11-18 PA PA19978441701A patent/PA8441701A1/es unknown
- 1997-11-19 BR BR9713538A patent/BR9713538A/pt not_active Application Discontinuation
- 1997-11-19 EP EP97910602A patent/EP0944611B1/en not_active Expired - Lifetime
- 1997-11-19 ES ES97910602T patent/ES2213207T3/es not_active Expired - Lifetime
- 1997-11-19 JP JP10524469A patent/JP3120861B2/ja not_active Expired - Fee Related
- 1997-11-19 WO PCT/IB1997/001465 patent/WO1998023603A1/en not_active Ceased
- 1997-11-19 DK DK97910602T patent/DK0944611T3/da active
- 1997-11-19 AU AU47924/97A patent/AU4792497A/en not_active Abandoned
- 1997-11-19 PE PE1997001052A patent/PE17099A1/es not_active Application Discontinuation
- 1997-11-19 CA CA002272927A patent/CA2272927C/en not_active Expired - Fee Related
- 1997-11-19 PT PT97910602T patent/PT944611E/pt unknown
- 1997-11-19 AT AT97910602T patent/ATE257472T1/de not_active IP Right Cessation
- 1997-11-19 DE DE69727155T patent/DE69727155T2/de not_active Expired - Fee Related
- 1997-11-20 AP APAP/P/1997/001148A patent/AP9701148A0/en unknown
- 1997-11-24 AR ARP970105494A patent/AR010304A1/es unknown
- 1997-11-25 ID IDP973762A patent/ID18964A/id unknown
- 1997-11-25 GT GT199700123A patent/GT199700123A/es unknown
- 1997-11-25 MA MA24872A patent/MA26450A1/fr unknown
- 1997-11-25 TN TNTNSN97191A patent/TNSN97191A1/fr unknown
- 1997-11-25 ZA ZA9710587A patent/ZA9710587B/xx unknown
- 1997-11-26 HR HR60/031,815A patent/HRP970640A2/hr not_active Application Discontinuation
- 1997-11-26 HN HN1997000154A patent/HN1997000154A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69727155D1 (de) | 2004-02-12 |
| ATE257472T1 (de) | 2004-01-15 |
| CA2272927A1 (en) | 1998-06-04 |
| JP3120861B2 (ja) | 2000-12-25 |
| CA2272927C (en) | 2003-02-04 |
| MA26450A1 (fr) | 2004-12-20 |
| HRP970640A2 (en) | 1998-10-31 |
| WO1998023603A1 (en) | 1998-06-04 |
| DE69727155T2 (de) | 2004-07-08 |
| DK0944611T3 (da) | 2004-04-13 |
| PE17099A1 (es) | 1999-02-19 |
| PA8441701A1 (es) | 2000-05-24 |
| GT199700123A (es) | 1999-05-19 |
| TNSN97191A1 (fr) | 2005-03-15 |
| AU4792497A (en) | 1998-06-22 |
| EP0944611B1 (en) | 2004-01-07 |
| HN1997000154A (es) | 1999-02-09 |
| ID18964A (id) | 1998-05-28 |
| ZA9710587B (en) | 1999-05-25 |
| AR010304A1 (es) | 2000-06-07 |
| BR9713538A (enExample) | 2000-03-21 |
| PT944611E (pt) | 2004-04-30 |
| ES2213207T3 (es) | 2004-08-16 |
| US5914329A (en) | 1999-06-22 |
| EP0944611A1 (en) | 1999-09-29 |
| JP2000505110A (ja) | 2000-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU9602721D0 (en) | Use of serotonin antagonists (5ht3) for treating fibromyalgia | |
| NO970162D0 (no) | Substituerte pyrimidinforbindelser og anvendelse derav | |
| MY131298A (en) | 5-heteroyl indole derivatives | |
| DE69526206D1 (de) | Verwendung von interleukin-12 fuer die verhinderung von transplantat gegen empfaengerkrankheit | |
| BG101112A (bg) | Използване на хетероциклени съединения | |
| TW290443B (enExample) | ||
| DK0464558T3 (da) | Antimigræne-alkoxypyrimidinderivater | |
| DE69941154D1 (de) | Verwendung von Hydroxamatverbindungen zur Behandlung von HER-2/neu positiven Karzinomen | |
| DE69534908D1 (de) | Verwendung von statin zur behandlung von hauterkrankungen | |
| ATE242234T1 (de) | Bicyclische arylcarboxamide und ihre therapeutische verwendung | |
| ATE210447T1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
| FI971127A7 (fi) | 2,4-diaminopyrimidiini-3-oksidin tai jonkin sen suolan käyttö kollagee nin kypsymis- ja rakentumishäiriöiden hoitamiseen | |
| AP9701148A0 (en) | Dimesylate salts of neuropeptide Y ligands. | |
| ID23175A (id) | Penggunaan benzopiranol untuk mengobati gangguan syaraf | |
| MY105555A (en) | Heterocyclicguanidines as 5ht 3 antagonists. | |
| DE69518438D1 (de) | Behandlung von übereregten nervenzellenfunktionen | |
| ZA931099B (en) | Heterocyclic compounds their use and preparation | |
| ES2150564T3 (es) | Proceso para la preparacion de derivados de 5,6-dihidroxi-2-amino-1,2,3,4-tetrahidronaftaleno. | |
| AP2000001963A0 (en) | Paroxetine ascorbate. | |
| FI965171A7 (fi) | Oksatsofosforiinien, esimerkiksi ifosfamidin, enantiomeerien käyttö ka svainten hoidossa sivuvaikutuksien vähentämiseksi | |
| DE69302250D1 (de) | Verwendung von Isoquinolinon-Derivaten zur Behandlung von Hyperlipoproteinemia | |
| EP0210099A3 (en) | Use of n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamide in the treatment of parkinsons's disease | |
| ECSP972321A (es) | Sales dimesilato de los ligandos del neuropeptido y antecedentes de la invencion | |
| DE69905731D1 (de) | Analgetische verwendung von podophylotoxin zur schmerzbehandlung der weiblichen genitalorgane | |
| MX9706424A (es) | Uso de la moxonidina para el tratamiento de la aterosclerosis. |